NCT06561685 2026-02-10A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Recruiting340 enrolled
NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled